Biomedicines (Mar 2022)

Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer

  • Lorena García-Hevia,
  • Débora Muñoz-Guerra,
  • Íñigo Casafont,
  • Carmelo Morales-Angulo,
  • Victor J. Ovejero,
  • David Lobo,
  • Mónica L. Fanarraga

DOI
https://doi.org/10.3390/biomedicines10040732
Journal volume & issue
Vol. 10, no. 4
p. 732

Abstract

Read online

Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.

Keywords